Allogene Therapeutics, Inc. (ALLO): Price and Financial Metrics
ALLO Price/Volume Stats
| Current price | $1.87 | 52-week high | $5.78 |
| Prev. close | $1.84 | 52-week low | $1.78 |
| Day low | $1.78 | Volume | 4,992,600 |
| Day high | $1.93 | Avg. volume | 2,487,024 |
| 50-day MA | $2.48 | Dividend yield | N/A |
| 200-day MA | $2.85 | Market Cap | 392.09M |
ALLO Stock Price Chart Interactive Chart >
Allogene Therapeutics, Inc. (ALLO) Company Bio
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, a CAR T cell product candidate targeting CD19, which is in clinical trials in patients with R/R B-cell precursor acute lymphoblastic leukemia; ALLO-501, an allogeneic anti-CD19 CAR T cell product candidate for the treatment of patients with R/R non-Hodgkin lymphoma; ALLO-715, an allogeneic CAR T cell product candidate for the treatment of patients with R/R multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepleting agent. It is also developing ALLO-819, an anti-Flt3 product candidate for the treatment of acute myeloid leukemia; CD70 for the treatment of renal cell cancer; and DLL3 for the treatment of small cell lung cancer. The company was founded in 2017 and is based in South San Francisco, California.
ALLO Price Returns
| 1-mo | -11.37% |
| 3-mo | -33.21% |
| 6-mo | -28.35% |
| 1-year | -38.89% |
| 3-year | -87.94% |
| 5-year | -93.01% |
| YTD | -41.74% |
| 2023 | -48.97% |
| 2022 | -57.84% |
| 2021 | -40.89% |
| 2020 | -2.85% |
| 2019 | -3.53% |
Loading social stream, please wait...